Clinical Medicine 2014-08-01

'Designer drugs': update on the management of novel psychoactive substance misuse in the acute care setting.

Christopher D Smith, Stefanie Robert

Index: Clin. Med. 14(4) , 409-15, (2014)

Full Text: HTML

Abstract

The use of novel psychoactive substances ('legal highs' or 'designer drugs') is increasing worldwide. Patients misusing such substances have been reported to experience severe or prolonged side effects requiring admission to acute or critical care wards. These complications can be life threatening if misdiagnosed or mismanaged. As physicians have traditionally had less involvement with the management of such patients compared with their colleagues in emergency departments an update in the management of such patients is indicated. Here we present a summary of the management of those novel substances with the potential for serious complications based on a review of current literature. © 2014 Royal College of Physicians.


Related Compounds

Related Articles:

An improved design of water-soluble propofol prodrugs characterized by rapid onset of action.

2014-04-01

[Anesth. Analg. 118(4) , 745-54, (2014)]

Treatment of alcohol dependence: recent progress and reduction of consumption.

2014-12-01

[Minerva Med. 105(6) , 447-66, (2014)]

Discriminative stimulus effects of the GABAB receptor-positive modulator rac-BHFF: comparison with GABAB receptor agonists and drugs of abuse.

2013-03-01

[J. Pharmacol. Exp. Ther. 344(3) , 553-60, (2013)]

Effects of monocarboxylate transporter inhibition on the oral toxicokinetics/toxicodynamics of γ-hydroxybutyrate and γ-butyrolactone.

2013-04-01

[J. Pharmacol. Exp. Ther. 345(1) , 102-10, (2013)]

The clinical toxicology of γ-hydroxybutyrate, γ-butyrolactone and 1,4-butanediol.

2012-07-01

[Clin. Toxicol. (Phila.) 50(6) , 458-70, (2012)]

More Articles...